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Abstract: HIV-associated sensory neuropathy (HIV-SN) is a disabling complication of HIV disease
and antiretroviral therapies (ART). Since stavudine was removed from recommended treatment
schedules, the prevalence of HIV-SN has declined and associated risk factors have changed. With
stavudine, rs1799964*C (TNF-1031) associated with HIV-SN in Caucasians and Indonesians but not in
South Africans. Here, we investigate associations between HIV-SN and rs1799964*C and 12 other
polymorphisms spanning TNF and seven neighboring genes (the TNF-block) in Indonesians (n = 202;
34/168 cases) and South Africans (n = 75; 29/75 cases) treated without stavudine. Haplotypes were
derived using fastPHASE and haplotype networks built with PopART. There were no associations
with rs1799964*C in either population. However, rs9281523*C in intron 10 of BAT1 (alternatively
DDX39B) independently associated with HIV-SN in Indonesians after correcting for lower CD4 T-cell
counts and >500 copies of HIV RNA/mL (model p = 0.0011, Pseudo R2 = 0.09). rs4947324*T (between
NFKBIL1 and LTA) independently associated with reduced risk of HIV-SN and shared haplotype 1
(containing no minor alleles) associated with increased risk of HIV-SN after correcting for greater
body weight, a history of tuberculosis and nadir CD4 T-cell counts (model: p = 0.0003, Pseudo
R2 = 0.22). These results confirm TNF-block genotypes influence susceptibility of HIV-SN. However,
critical genotypes differ between ethnicities and with stavudine use.
Keywords: HIV; sensory neuropathy; TNF-block; 8.1 ancestral haplotype; DDX39B and BAT1
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1. Introduction
HIV-associated sensory neuropathy (HIV-SN) is a disabling complication of HIV disease and its
treatment. It predominately affects nerve fibers that innervate the distal limbs, particularly the feet [1].
Symptoms include pain, burning and numbness, which impact an individual’s quality of life and
ability to work [2,3]. Nucleoside reverse transcriptase inhibitors (NRTI) are effective anti-retroviral
therapies (ART) but some, most notably stavudine (d4T), have severe adverse effects, including sensory
neuropathy and lipodystrophy [4]. The prevalence of HIV-SN varied from 19% to 57% in patients
exposed to stavudine [5–9]. Stavudine has not been recommended since 2010 due to its toxicity and a
reduction in HIV-SN cases have been noted but not well documented.
We compared the prevalence of HIV-SN assessed with the AIDS Clinical Trial Group Brief
Peripheral Neuropathy Screening Tool in HIV+ patients treated at an inner-city clinic in Jakarta,
Indonesia with stavudine in 2006 and without stavudine in 2016 [10]. A patient’s height and age were
associated with HIV-SN among patients receiving stavudine, and 34% experienced neuropathy [5].
In 2016, the prevalence of HIV-SN was 14.2% among patients who had not been exposed to stavudine.
Most patients (94%) had <500 copies HIV RNA/mL plasma, but >500 copies HIV RNA/mL and a
nadir of below 200 CD4 T-cells/µL associated with HIV-SN. Thus, HIV-SN still presents in patients
treated without stavudine, but the prevalence is lower, and the risk factors are markers of HIV disease
severity. With the same screening test, the prevalence of HIV-SN was higher (57%) in South African
patients receiving stavudine, and was linked with age and height, as in Indonesia [9]. The prevalence
of HIV-SN without stavudine in this setting is unclear.
Tumor necrosis factor alpha (TNF) expression has been demonstrated histologically in specimens
from individuals with sensory fiber, axonal and/or demyelinating neuropathies, particularly when
there was pain [11]. Its role in HIV patients is supported by evidence that the application of HIV gp120
to the sciatic nerve of a rat upregulated expression of TNF, CXCR4 and CXCL12 in the dorsal root
ganglia and the lumbar spinal dorsal horn. A non-replicating herpes simplex virus vector encoding the
p55TNFSR gene (producing a TNF-soluble receptor able to block TNF bioactivity) reversed mechanical
allodynia [12]. Since HIV patients display elevated levels of TNF and its soluble receptor in plasma [13],
a role in HIV-SN is plausible. However, TNF is difficult to visualize in skin biopsies—perhaps because
expression is transient. Genetic associations provide a signature that is stable over time.
The gene encoding TNF (TNF) lies in the central MHC in a defined region of high linkage
disequilibrium (LD; the TNF-block), which contains several potentially pro-inflammatory genes
(TNF, LTB, LTA, NCR3, LST1, NFKBIL1, ATP6V1G2, BAT1 (alternatively DDX39B) and MCCD1) [14].
Carriage of the minor allele at TNF-1031 (rs1799964) associated with increased risk of HIV-SN in
Caucasians, Chinese and Malays who had received stavudine [5,6,15], but not in South Africans [16].
We characterized TNF-block haplotypes in multiple ethnicities and showed that the haplotype
containing the minor allele of TNF-1031 in Asians and Caucasians was not present in Africans [14,16].
This implicates an allele carried in linkage with TNF-1031 in its associations with HIV-SN.
Here, Indonesian and South African HIV patients treated without stavudine are assessed to identify
single nucleotide polymorphisms (SNP) and haplotypes of the TNF-block associated with HIV-SN.
In addition to TNF-1031, we consider markers of the Caucasian 8.1 ancestral haplotype (AH; HLA
A*0101: Cw*0701: B*0801: DRB1*0301: DQA1*0501: DQB1*0201), which has been associated with many
immunopathological conditions including diabetes and coeliac disease [17]. The most studied candidate
polymorphism lies at position -308 upstream of TNF (TNF-308; rs1800629). Despite several promising
ex vivo studies, alleles of rs1800629 did not affect TNF production when analyzed using promotor
constructs [18], so other SNP within the conserved haplotype may be important. As rs1800629*A occurs
in several TNF-block haplotypes, we use an indel in intron 10 of the BAT1/DDX39B gene (rs9281523*C)
as a specific marker of the TNF-block of the 8.1AH [14]. In Asians, the minor alleles of rs1800629 and
rs9281523 occur as part of the diabetogenic 8.1 AH [19,20], consistent with a role for the region in
immunopathology. The minor allele of rs9281523 associated with risk of HIV-SN in Caucasian patients
who developed a toxic neuropathy following exposure to stavudine [6], but showed no effect in our
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cross-sectional studies of Indonesian or South African patients treated with stavudine [5,16]. Here,
we assess two cohorts with no exposure to stavudine.
Parallel investigation in two cohorts of different ethnicity has potential to identify critical SNP
within conserved haplotypes. Specifically, instances where the predominant haplotypes vary, but the
same SNP associates with the phenotype provide circumstantial evidence that the SNP contributes
directly to the phenotype.
2. Results
2.1. Measures of the Severity of HIV Disease Predict HIV-SN in Indonesians and Africans
The South African cohort (n = 75) included 29 patients with HIV-SN (38.7%). Participants were
relatively young [39 (19–60)] and 60% were female (45/75). Patients with HIV-SN were a little heavier
and taller than those without. Height, weight and lower nadir CD4 T-cell counts associated significantly
(p < 0.05) with HIV-SN. A lower current CD4 T-cell count, a history of tuberculosis and >500 copies
of HIV RNA/mL associated weakly (p < 0.20) with HIV-SN (Table 1). The regression model retained
greater weight, tuberculosis and a low nadir CD4 T-cell count independently associated with HIV-SN
(model p = 0.0007; pseudo R2 = 0.18; Table S1).
The Indonesian cohort (n = 202) included 34 patients with HIV-SN (16.8%). Participants were
relatively young [35 years (19–60 years)] and 29% were female (58/202). A lower current CD4 T-cell
count and >500 copies of HIV RNA/mL were significantly associated with HIV-SN in bivariate analyses
(p < 0.05; Table 1). A lower nadir CD4 T-cell count and a history of tuberculosis were weakly linked
with HIV-SN (p < 0.20) and were also included multivariate analyses. The regression model identified a
current viral load >500 copies of HIV RNA/mL and a lower current CD4 T-cell count as independently
associated with HIV-SN (p = 0.0006; pseudo R2 = 0.08; Table S1) [21].
We note that height was associated with HIV-SN in African and Indonesian patients treated with
stavudine. Here, in Indonesians, height was excluded from logistic regression modeling as it did not
meet inclusion criteria (p = 0.71; Table 1). However, in Africans, height met criteria for inclusion in
logistic regression modelling (p = 0.03; Table 1) but was not retained in the optimal model. It is unlikely
that associations with body weight in the optimal model in Africans arise through correlations with
height (Pearson’s r = 0.225, p = 0.06).
Table 1. HIV-SN associates with CD4 T-cell counts and control of HIV replication.
Variable
Africans Indonesians
HIV-SN HIV-SN
+ve
(n = 29)
−ve
(n = 46) p
a,b +ve
(n = 34)
−ve
(n = 167) p
a,b
Age (years) 40 (24–60) 37 (19–58) 0.11 36 (21–59) 35 (19–60) 0.68
Height (cm) 168(147–179)
163
(135–186)
n = 45
0.03 167(151–185)
167 (142–180)
n = 166 0.71
Weight (kg) 66 (45–112) 55 (35–110)n = 44 0.03 59 (39–88)
58.5 (37–104)
n = 166 1.00
Current CD4
T-cells/µL 221 (22–685) 300 (8–832) 0.06 326 (44–729)
458
(84–1166) 0.003
Nadir CD4
T-cells/µL 107 (4–575) 223 (8–771) 0.002 54 (3–428)
121 (1–599)
n = 165 0.06
HIV RNA >500 copies/mL 21/29 (72%) 25/46 (54%) 0.12 6/29 (17%) 7/163 (4.1%) 0.005
History of Tuberculosis 6/28 (29%) 3/45 (7%) 0.08 c 18/35 (53%) 66/168 (39%) 0.09
Female Gender 15/29 (52%) 30/46 (65%) 0.25 9/35 (26%) 49/167 (29%) 0.98
a Mann-Whitney test used to assess all continuous variables—Median (range); b χ2 test used to assess dichotomous
variables—Proportion (%); c Fisher’s Exact test used where n < 5; Shading marks factors included in logistic
regressions. Significant differences are shown in bold font.
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2.2. Two Alleles Associated with HIV-SN in Indonesians but not Africans
Thirteen SNP previously linked with HIV-SN either independently or within haplotypes were
selected from across the TNF-block for genotyping in these cohorts (Table 2) [6,15,16]. In the Indonesian
cohort, the minor alleles of rs9281523 (DDX39B/BAT1(intron10)) and rs1800629 (TNF-308) were more
common in patients with HIV-SN. These alleles were in tight LD but the minor allele of rs1800629 also
occurred alone, so only rs9281523*C was included in logistic regressions as it reflects carriage of both
alleles. No other SNP attained p < 0.20—the cut-off for inclusion in logistic regressions. The optimal
model included >500 copies HIV RNA/mL, a lower current CD4 T-cell count and the minor allele of
rs9281523 (p = 0.0011, pseudo R2 = 0.09; Table 3).
Minor alleles of rs2981523 and rs1800629 were present at higher frequencies but were not associated
with HIV-SN in Africans (Table 2). However weak associations with reduced risk (p < 0.20) were
evident with rs4947324*T (between NFKBIL1 and LTA) and rs1041981*C (in LTA). These were included
in logistic regression modeling. The resulting model (p = 0.003, pseudo R2 = 0.23; Table 4) incorporated
weight, tuberculosis, lower nadir CD4 T-cell count and rs4947324*T.
Table 2. Alleles of two SNP associate with HIV-SN in Indonesians but not Africans.
SNP rsID
Africans (n = 75) Indonesians (n = 202)
Minor Allele MAF a
HIV-SN
p e Minor Allele MAF a
HIV-SN
p d
+ve b −ve +ve b −ve c
rs2075582
(MCCD1) C 0.13
7/28 d
(25%)
12/46
(27%) 0.87 C 0.34
19/34 e
(56%)
94/166
(57%) 0.97
rs9281523
(DDX39B) - 0.20
9/29
(31%)
17/46
(37%) 0.60 - 0.03
5/29
(17%)
8/166
(5%) 0.03
rs11796
(DDX39B) A 0.41
16/29
(55%)
31/46
(67%) 0.27 T 0.35
21/35
(60%)
95/167
(57%) 0.73
rs2523506
(DDX39B) T 0.12
6/28
(21%)
9/46
(20%) 0.85 T 0.34
13/34
(38%)
70/165
(42%) 0.65
rs2523504
(intergenic) T 0.17
8/29
(28%)
15/46
(33%) 0.60 T 0.33
19/35
(54%)
92/165
(56%) 0.87
rs2071594
(intergenic) G 0.41
16/29
(55%)
31/46
(67%) 0.29 C 0.37
21/35
(60%)
98/165
(59%) 0.95
rs2071593
(intergenic) A 0.07
2/29 f
(7%)
8/46
(17%) 0.30 A 0.12
7/34
(21%)
38/167
(23%) 1.00
rs2071592
(NFKBIL1) T 0.42
16/29
(55%)
30/46
(67%) 0.32 A 0.30
19/34
(56%)
83/166
(50%) 0.53
rs4947324
(intergenic) T 0.16
6/29
(21%)
16/46
(35%) 0.19 T 0.03
3/35
(9%)
8/166
(5%) 0.41
rs909253
(LTA) A 0.41
16/29
(55%)
31/46
(67%) 0.29 G 0.36
21/35
(60%)
99/167
(59%) 0.94
rs1041981
(LTA) C 0.39
15/29
(52%)
30/46
(67%) 0.20 A 0.36
21/35
(60%)
99/167
(59%) 0.94
rs1799964
(intergenic) C 0.15
6/29
(21%)
12/46
(27%) 0.56 C 0.27
16/35
(46%)
76/165
(46%) 0.97
rs1800629
(intergenic) A 0.23
10/29
(34%)
19/46
(41%) 0.56 A 0.04
6/35
(17%)
11/167
(7%) 0.04
a MAF: minor allele frequency; b Individuals with HIV-SN who carry one or two copies of the minor allele;
c Individuals without HIV-SN who carry one or two copies of the minor allele; d χ2 or Fisher’s Exact test if n < 5;
e Up to six samples failed to genotype for each SNP; f Two SNP in Indonesians which associated with HIV-SN
(p < 0.05) are in bold; Two SNP in Indonesians and two SNP in Africans which met the criteria for inclusion in
logistic regression modelling (p < 0.20) are shaded.
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Table 3. Logistic regression modelling identified rs9281523*C in Indonesians as an independent marker
of susceptibility to HIV-SN.
Variable Odds Ratio p Value 95% Confidence Interval
SNP Model: n = 193 a, p = 0.0011, Pseudo R2 = 0.09
Current CD4 T-cells/µL 1.00 0.02 1.00–1.00
>500 copies HIV RNA/mL 1.86 0.12 0.85–4.07
rs9281523*C 2.49 0.15 0.71–8.65
Haplotype Model: No haplotypes independently associated with HIV-SN after
correction for current CD4 T-cells/µL and >500 copies of HIV RNA/mL
a Excluding samples with missing demographic, clinical and/or genotype data.
Table 4. Logistic regression modelling identified rs4947324*T in Africans as an independent marker of
susceptibility to HIV-SN.
Variable Odds Ratio p Value 95% Confidence Interval
SNP Model: n = 71 a, p = 0.0003, Pseudo R2 = 0.23
Weight (kg) 1.04 0.04 1.00–1.08
History of Tuberculosis 5.66 0.04 1.09–29.36
Nadir CD4 T-cells/µL 0.99 0.02 0.99–1.00
rs4947324*T 0.25 0.05 0.06–1.01
Haplotype Model: n = 71 a, p = 0.0003, Pseudo R2 = 0.22
Weight (kg) 1.04 0.02 1.01–1.08
History of Tuberculosis 5.22 0.04 1.09–24.86
Nadir CD4 T-cells/µL 0.99 0.02 0.99–1.00
S1 (Shared Haplotype 1) 3.21 0.07 0.93–11.12
a Excluding samples with missing demographic, clinical, genotype data and/or haplotypes perfectly aligned with
the absence of HIV-SN.
2.3. One Haplotype Containing rs9281523*C and rs1800629*A Associated with HIV-SN in Indonesians but
Not Africans
FastPHASE generated 10 haplotypes in Indonesians and 12 haplotypes in Africans present at
>1.0%. These accounted for 98% and 96% of each population, respectively (Tables 5 and 6). Eight
haplotypes were shared between the two populations (S1–S8) and are numbered in order of the
frequency of each haplotype in Africans. An additional four haplotypes were unique to Africans
(A1–A4) and two were unique to Indonesians (I1, I2).
The haplotype S2 contained the minor alleles of rs9281523 and rs1800629, and associated with
HIV-SN in bivariate analyses of the Indonesian cohort (Table 5) but did not remain in the final model
(Table 3). This haplotype was also common in Africans but was not linked with HIV-SN. Three other
haplotypes (S1, A3 and S7) carried by Africans met the criterion for inclusion in logistic regression
models (p < 0.20; Table 6). However, A3 and S7 perfectly predicted the absence of HIV-SN and could
not be included. The resulting model (p = 0.0003, pseudo R2 = 0.22; Table 4) included greater body
weight, prior TB, lower nadir CD4 T-cell counts and S1. S1 contains no minor alleles.
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Table 5. One haplotype associated with HIV-SN in Indonesians.
H
ap
lo
ty
pe
a
rs
20
75
58
2
rs
92
81
52
3
rs
11
79
6
rs
25
23
50
6
rs
25
23
50
4
rs
20
71
59
4
rs
20
71
59
3
rs
20
71
59
2
rs
49
47
32
4
rs
90
92
53
rs
10
41
98
1
rs
17
99
96
4
rs
18
00
62
9 HIV-SN b
pc
+ve
(n = 35)
−ve
(n = 167)
S1 T - T G C C G A C G A T G 15 43% 72 43% 0.69
S3 T - A T C G G T C A C C G 14 40% 70 42% 0.85
S4 C - A G T G G T C A C T G 12 34% 60 36% 0.87
S8 C - A G T G A T C A C T G 7 20% 36 22% 0.97
I1 T - T G C C G T C G A T G 3 9% 21 13% 0.77
S6 T - A G C G G T C A C T G 2 6% 10 6% 0.99
S2 d T C T G C C G A C G A T A 5 14% 8 5% 0.02
S7 T - A G C G G T T A C C G 2 6% 8 5% 0.66
I2 C - A G C C G A C G A T G 0 0% 5 3% 0.99
S5 T - T G C C G A C G A T A 1 3% 3 2% 0.51
a Haplotypes shared between Africans and Indonesians are labelled S1–S8 in order of their population frequencies
in Africans. Haplotypes unique to Indonesians are labelled I1 and I2 in order of population frequencies. Haplotypes
carried at <1% are excluded. Minor alleles for each population are shaded grey; b Number of individuals who carry
one or two copies of each haplotype; c χ2 (or Fisher’s Exact test if n < 5); d Haplotypes meeting logistic regression
criteria (p < 0.20) are in bold.
Table 6. Three haplotypes were weakly associated with HIV-SN in Africans.
H
ap
lo
ty
pe
a
rs
20
75
58
2
rs
92
81
52
3
rs
11
79
6
rs
25
23
50
6
rs
25
23
50
4
rs
20
71
59
4
rs
20
71
59
3
rs
20
71
59
2
rs
49
47
32
4
rs
90
92
53
rs
10
41
98
1
rs
17
99
96
4
rs
18
00
62
9 HIV-SN b
pc
+ve
(n = 29)
−ve
(n = 46)
S1 d T - T G C C G A C G A T G 19 66% 23 50% 0.19
S2 T C T G C C G A C G A T A 9 31% 16 35% 0.34
S3 T - A T C G G T C A C C G 5 17% 8 17% 0.99
A1 T - A G C G G T T A C T G 3 10% 8 17% 0.51
S4 C - A G T G G T C A C T G 3 10% 5 11% 0.99
S5 T - T G C C G A C G A T A 1 3% 4 9% 0.64
A2 C - A G T G A T T A C T G 1 3% 4 9% 0.64
S6 T - A G C G G T C A C T G 3 10% 2 4% 0.37
A3 T - T G T C G A C G A T G 0 0% 4 9% 0.15
S7 T - A G C G G T T A C C G 0 0% 4 9% 0.15
S8 C - A G T G A T C A C T G 0 0% 2 4% 0.52
A4 C - A G T G G T C A A T G 0 0% 2 4% 0.52
a Haplotypes shared between Africans and Indonesians are labelled S1–S8 in order of their population frequencies
in Africans. Haplotypes unique to Africans are labelled A1–A4 in order of population frequencies. Haplotypes
carried at <1% are excluded. Minor alleles for each population are shaded grey; b Number of individuals who carry
one or two copies of each haplotype; c χ2 (or Fisher’s Exact test if n < 5); d Haplotypes meeting logistic regression
criteria (p < 0.20) are in bold.
2.4. One Haplogroup Contained the Two Haplotypes Associated with HIV-SN in Africans and Indonesians
A haplotype network was constructed for the 14 haplotypes occurring at >1% in Africans or
Indonesians; S1–S8, A1–A4 and I1–I2. The haplotype network identified two haplogroups (A and B),
where each contained two shared haplotypes and one unique to Africans (Figure 1).
Haplogroup A included S1, S2 and A3—carried by 91% of the Africans and 50% of Indonesians.
S1 associated with HIV-SN in Africans and S2 with HIV-SN in Indonesians (Tables 5 and 6). S1 and
S2 differ only at rs9281523 (DDX39B/BAT1 (intron10)) and rs1800629 (TNF-308), marking the 8.1AH.
A3 perfectly predicted the absence of HIV-SN in Africans.
Haplogroup B contained S4, S8 and A2, and was carried by 20% of Africans and 57% of Indonesians.
S8 was also not observed in Africans with HIV-SN. These three haplotypes share seven minor alleles
and differ at a further two loci: S8 and A2 include the minor allele of rs2071593 and A2 carries the
minor allele of rs4947324, which are associated with reduced risk of HIV-SN in Africans (Table 2).
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with increased risk of HIV-SN in Africans in bivariate analyses (Table 6). b Associated with increased
risk of HIV-SN in Indonesians in bivariate analyses (Table 5). c Haplotypes not found in Africans with
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3. Discussion
Despite the discontinuation of stavudine, HIV-SN remains a common neurological complication
of HIV disease, impacting 14% of Indonesians surveyed in the 2016 cross-sectional study [10] and
38% of Africans n this study. We describe a sociations etween HIV-SN and demographic variables,
clinical variables and SNP and haplotypes in the TNF-block which have previously been linked with
HIV-SN in Caucasians, Asians and Africans.
Age and height were strong predictors of HIV-SN in Africans and Indonesians treated with
stavudine [5,9]. However, without stavudine, markers of HIV disease severity were more clearly
associated with HIV-SN. In African patients, the optimal markers were lower nadir CD4 T-cell counts,
greater weight and a history of tuberculosis whilst low current CD4 T-cell counts and >500 HIV
RNA copies/mL were the clearest associations with HIV-SN in Indonesians. As the African patients
had received ART for only 6–8 months, current CD4 T-cell levels may not have stabilized and a
clearer association with nadir CD4 T-cell counts is reasonable. In Africans, tuberculosis remained
independently associated with HIV-SN in all regression models (Table S1 and Table 4), despite being
present in 41% of Indonesians (cf 15% of Africans) and associated weakly with HIV-SN in both
populations in bivariate analyses (Table 1). Pyridoxine is routinely provided to patients treated for
tuberculosis in South Africa and Indonesia, but a previous South African study linked inadequate
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levels of pyridoxine with neuropathy despite administration of supplements [22]. Overall, biological
markers of HIV disease were the clearest demographic and clinical associations of HIV-SN. This is
consistent with findings prior to the advent of ART (and hence, stavudine) [23] and suggests the
underlying mechanisms of HIV-SN may differ between patients treated with and without stavudine.
Differences in the pathogenic pathways are also evidenced by the different genetic associations
identified in this study. We found no associations between the minor allele of rs1799964 (TNF-1031)
and HIV-SN in Africans or Indonesians evident in our studies of Asians and Caucasians treated with
stavudine [5,6,15]. In Indonesians treated without stavudine, rs9281523*C (DDX39B/BAT1 (intron10))
is independently associated with HIV-SN after correcting for lower current CD4 T-cell counts and
>500 copies of HIV RNA/mL (model p = 0.0011, Pseudo R2 = 0.09; Table 3). The S2 haplotype, which
contains rs9281523*C, was associated with HIV-SN in Indonesians in bivariate analyses. rs9281523*C
marks the 8.1AH which has been linked with accelerated loss of CD4 T-cells and impaired recovery
following HIV infection [24,25] and with numerous immunopathological diseases [17,26]. So, a link
with HIV-SN is plausible and the search for the SNP responsible has wide ramifications. A direct role
for rs9281523 is supported by its inclusion in the optimal model for Indonesians, while the associated
haplotype (S2) was excluded. However, S2 and S1 (the haplotype linked with risk of HIV-SN in
Africans) differed only at rs9281523 and rs1800629 and occurred in the same haplogroup (Figure 1).
This suggests the haplotypes may have descended from a common ancestor, but argues against a direct
role for rs9281523 or rs1800629. It also fits with the observation that rs9281523 shows no associations
with HIV-SN in Africans.
In Africans, the minor alleles of rs4947324*T and rs1041981*C associated weakly with reduced
risk of HIV-SN in bivariate analyses (Table 2). Both SNP have been associated with reduced risk of
HIV-SN in South Africans treated with stavudine where rs1041981*C and six additional SNP from
the TNF-block were included in the logistic regression model with age and height [16]. Without
stavudine, rs4947324*T alone remained in the optimal model (p = 0.0003, Table 4). Three haplotypes
(S1, A3 and S7) were weakly associated with altered risk of HIV-SN (p < 0.20; Table 6). A3 and S7
were rare haplotypes with no minor alleles in common, but S7 contained rs4947324*T and rs1041981*C.
Neither A3 nor S7 occurred in patients with HIV-SN so they could not be included in logistic regression
modeling. S1, was independently associated with risk of HIV-SN in the final model along with greater
weight, tuberculosis and nadir CD4 T-cells/µL (p = 0.0003, Pseudo R2 = 0.22; Table 4). S1 included no
minor alleles and therefore contained the major (*C) risk allele of rs4947324.
The search for SNP responsible for associations with TNF-block haplotypes is complicated
by the lack of relevant in vitro assays for chronic conditions. For example, haplotypes containing
polymorphisms within the TNF-block were associated with altered TNF and lymphotoxin-alpha
production in cultured mononuclear cells from Australian Caucasians but haplotypes containing
rs9281523*C and rs4947324*T had no impact [27]. SNP within the TNF-block may also impact other
MHC genes. The GTEX eQTL database reports altered expression of several immune-related genes
within the MHC is associated with carriage of rs9281523*C or rs4947324*T including C4A, HLA-C and
MICB (https://gtexportal.org/). However, understanding the biological consequences of these SNP and
associated haplotypes is complicated by LD within the region [28].
We recognize the small size of our cohorts, but strict inclusion criteria avoided alternative causes
of neuropathy. Further studies are required to validate our findings in larger cohorts when they
become available, and to address the biological implications. Overall, we confirm that HIV-SN
remains a clinically relevant problem in HIV+ patients treated without stavudine and is more common
in those with African ancestry. We confirm that TNF-block genotypes associate with HIV-SN but
show that different mechanisms are invoked with and without stavudine. Critical genotypes differ
between Indonesians and Africans so the causative alleles remain unknown. However, the haplotypes
associated with HIV-SN may descend from a common ancestor, and therefore, include allele/s not
typed in our panel. Associations with TNF-block haplotypes per se confirm the inflammatory etiology
of HIV-SN. Moreover, the clearer associations with HIV-SN seen in Africans (evidenced by stronger
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regression models) may plausibly align with the greater frequency of HIV-SN in Africans compared
with Indonesians. This distinction warrants further investigation.
4. Materials and Methods
4.1. Participants and Phenotypes
HIV-positive adults (n = 185) who had used ART for at least 12 months with no exposure to
stavudine were screened for neuropathy at POKDISUS HIV Care Clinic, Cipto Mangunkusumo
Hospital, Jakarta, Indonesia in 2016 [21,29]. Patients with any history of other conditions potentially
linked with neuropathy were excluded. DNA was also available from nine HIV+ patients with HIV-SN
and eight patients without HIV-SN matched by age, gender and CD4 T-cell count. These 17 individuals
were recruited in 2012 at the same clinic and met inclusion criteria for the present study. Patients
with African ancestry attending the Lenasia South Community Health Hospital, Johannesburg, South
Africa, were enrolled after 6–8 months on ART. These studies were approved by the Ethics Committee
of the Faculty of Medicine, Universitas Indonesia (approval number: (579/UN2.F1/ETIK/2014), and the
Human Research Ethics Committee (Medical) of the University of the Witwatersrand, Johannesburg
(approval number: MR121018-R14/49). Written informed consent was obtained in all cases.
HIV-SN was assessed using the AIDS Clinical Trials Group Brief Peripheral Neuropathy Screening
Tool, a validated metric for diagnosing HIV-SN [30]. HIV-SN was defined by bilateral presence
of at least one symptom (pain/burning/aching, numbness, and paresthesia) and one clinical sign
(absent reflexes and impaired vibration sense in the great toe). In South Africans, pinprick sensitivity
was added to the BPNS as it provides an assessment specific to small fiber pathology and has high
specificity for HIV-SN [31,32]. Clinical and demographic records were collected from medical files
to determine risk factors that may be linked with HIV-SN. This included the patient’s history of
tuberculosis as medications used in its treatment, notably isoniazid, competitively interferes with
pyridoxine metabolism and may result in peripheral neuropathy [22,33].
4.2. Genotyping
As described previously [21], genomic DNA was extracted from EDTA-blood samples using
Favorprep Blood Genomic DNA Extraction Mini Kits (Favorgen Biotech Corporation, Changzhi,
Taiwan) adjusted to 50 ng/µL and diluted 1:1 in TaqMan® OpenArray™ Genotyping Master Mix
(Life Technologies, Grand Island, NY, USA). Samples were genotyped for 13 SNP (Table 2) spanning
MMCD1, DDX39B, ATP6V1G2, NFKBIL1, LTA and TNF using the QuantStudio 12K Flex Real-Time PCR
System on custom TaqMan® OpenArrayTM Real-Time PCR Plates. All alleles were in Hardy-Weinberg
Equilibrium (HWE).
4.3. Haplotype Analyses
Haplotypes and their estimated frequencies were determined using the default parameters of
the fastPHASE algorithm [34], with haplotypes sampled from the observed genotypes an additional
5000 times per sample. Haplotypes with an estimated frequency less than 1% were excluded from
analyses. Haplotypes shared between Africans and Indonesians are labelled S1–S8 in order of their
population frequencies in Africans. Haplotypes unique to Africans are labelled A1–A4 and haplotypes
unique to Indonesians are labelled I1 and I2 in order of their respective population frequencies. PopART
version 1.7 (Population Analysis with Reticulate Trees, Otago, New Zealand; http://popart.otago.ac.nz)
was used to construct haplogroups using Median-Joining methods [35].
4.4. Statistical Analyses
Bivariate associations between HIV-SN and demographic or clinical variables, SNP and haplotypes
were assessed with t-tests, Mann-Whitney tests, Chi2 or Fisher’s exact tests using GraphPad Prism
version 8.2.1 for Windows (Graphpad Software, La Jolla, CA, USA). No corrections were made for
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multiple comparisons. All variables which weakly (p = 0.05–0.20) or significantly (p < 0.05) associated
with HIV-SN in bivariate analyses were included in logistic regression modelling. Optimal models
identifying variables independently associated with HIV-SN were determined with a stepwise removal
process using Stata/IC 16.0 for Windows (StataCorp LLC, College Station, TX, USA).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/2/380/s1.
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HIV Human immunodeficiency virus
HIV-SN HIV-associated sensory neuropathy
BPNS Brief peripheral neuropathy screening tool
TNF Tumor necrosis factor
CXCR4 C-X-C chemokine receptor type 4
CXCL12 C-X-C chemokine ligand 12
MHC Major histocompatibility complex
LD Linkage disequilibrium
LTB Lymphotoxin beta
LTA Lymphotoxin alpha
NCR3 Natural Cytotoxicity Triggering Receptor 3
LST1 Leukocyte-specific transcript 1
NFKBIL1 Nuclear Factor if Kappa Light Polypeptide Gene Enhancer In B-Cells Inhibitor-Like 1
DDX39B DExD-Box Helicase 39B
MCCD1 Mitochondrial Coiled-Coil Domain 1
AH Ancestral Haplotype
S1-8 Shared haplotypes 1-8
A1-4 African haplotypes 1-4
I1-2 Indonesian haplotypes 1 and 2
GTEX Genotype-Tissue Expression
eQTL Expression quantitative trait loci
C4A Complement Component 4A
HLA Human leukocyte antigen
MICB MHC class I polypeptide-related sequence
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